The Experts below are selected from a list of 18090 Experts worldwide ranked by ideXlab platform
Hermioni L Amonoo - One of the best experts on this subject based on the ideXlab platform.
-
does desire to pursue pleasurable activities matter the impact of pretransplantation Anhedonia on quality of life and fatigue in hematopoietic stem cell transplantation
Biology of Blood and Marrow Transplantation, 2020Co-Authors: Hermioni L Amonoo, Alyssa L Fenech, Joseph A Greer, Jennifer S Temel, Jeff C Huffman, Areej EljawahriAbstract:Anhedonia, the loss of the capacity to experience pleasure, is subjectively and biologically distinct from depressed mood. Few studies have specifically examined the association of pretransplantation Anhedonia with key functional outcomes (eg, health-related quality of life [QOL]) in patients with hematologic malignancies who have undergone hematopoietic stem cell transplantation (HSCT). Among 248 HSCT recipients enrolled in 2 intervention trials, we examined the associations between pretransplantation Anhedonia and both QOL and fatigue at 2 weeks and 6 months post-transplantation. Across time points, patients completed the Hospital Anxiety and Depression Scale, Functional Assessment of Cancer Therapy-Bone Marrow Transplant, and Functional Assessment of Cancer Therapy-Fatigue subscale, which we used to measure depressive symptoms, QOL and fatigue, respectively. Pretransplantation Anhedonia was assessed using the corresponding item in the Patient Health Questionnaire-9. The Functional Assessment of Cancer Therapy-Bone Marrow Transplant and the Functional Assessment of Cancer Therapy-Fatigue subscales were used to measure QOL and fatigue. Associations between pretransplantation Anhedonia and outcomes were assessed using regression analyses, adjusting for age, sex, transplant type, and intervention group. Ninety-eight patients (39.5%) reported pretransplantation Anhedonia, of whom 60 (61%) did not meet the criteria for elevated depressive symptoms. Pretransplantation Anhedonia was negatively associated with QOL at 2 weeks (B = -17.21; 95% confidence interval [CI], -23.05 to -11.30; P < .001) and at 6 months (B = -15.10; 95% CI, -21.51 to -8.69; P< .001). Pretransplantation Anhedonia was also negatively associated with fatigue (2 weeks: B = -9.35; 95% CI, -12.47 to -6.22; P< .001; 6 months: B = -5.68; 95% CI, -9.07 to -2.28; P= .001). The association between pretransplantation Anhedonia and QOL and fatigue remained significant after adjusting for depression scores. Pretransplantation Anhedonia is negatively and significantly associated with QOL and fatigue in HSCT recipients. These findings underscore the need to incorporate Anhedonia assessment in the evaluation and management of psychological distress in these patients.
-
does desire to pursue pleasurable activities matter the impact of pre transplant Anhedonia on quality of life and fatigue in hematopoietic stem cell transplantation
Biology of Blood and Marrow Transplantation, 2020Co-Authors: Hermioni L Amonoo, Alyssa L Fenech, Joseph A Greer, Jennifer S Temel, Jeff C Huffman, Areej EljawahriAbstract:BACKGROUND: Anhedonia, the loss of the capacity to experience pleasure, is subjectively and biologically distinct from depressed mood. Few studies have specifically examined the association of pre-transplant Anhedonia with key functional outcomes (e.g., health-related quality of life; QOL) in patients with hematologic malignancies who have received hematopoietic stem cell transplantation (HSCT). METHODS: Among 248 HSCT patients enrolled in two intervention trials, we examined the associations between pre-transplant Anhedonia and both QOL and fatigue at 2 weeks and 6 months post-transplant. Across time points, patients completed the Hospital Anxiety and Depression Scale, Functional Assessment of Cancer Therapy-Bone Marrow Transplant, and Functional Assessment of Cancer Therapy-Fatigue subscale, which we used to measure depressive symptoms, QOL and fatigue, respectively. Pre-transplant Anhedonia was assessed via the corresponding item in the Patient Health Questionnaire-9. The Functional Assessment of Cancer Therapy-Bone Marrow Transplant and the Functional Assessment of Cancer Therapy-Fatigue subscale were used to measure QOL and fatigue. Associations between pre-transplant Anhedonia and outcomes were assessed via regression analyses adjusting for age, gender, transplant type, and intervention group. RESULTS: 39.5% (n=98) of patients reported pre-transplant Anhedonia. Of the patients who reported pre-transplant Anhedonia, 61% (n=60) did not meet criteria for elevated depressive symptoms. Pre-transplant Anhedonia was negatively associated with QOL at 2 weeks (B=-17.21; 95% CI, -23.05 to -11.30; p<.001) and at 6 months (B=-15.10; 95% CI, -21.51 to -8.69; p<.001). Pre-transplant Anhedonia was also negatively associated with fatigue (2 weeks: B=-9.35; 95% CI, -12.47 to -6.22; p<.001; 6 months: B=-5.68; 95% CI, -9.07 to -2.28; p=.001). The association between pre-transplant Anhedonia and QOL and fatigue remained significant after adjusting for depression scores. CONCLUSIONS: Pre-transplant Anhedonia is negatively and significantly associated with QOL and fatigue in HSCT patients. These findings underscore the need to incorporate Anhedonia assessment in the evaluation and management of psychological distress in HSCT patients.
Athina Markou - One of the best experts on this subject based on the ideXlab platform.
-
Enduring deficits in brain reward function after chronic social defeat in rats: Susceptibility, resilience, and antidepressant response
Biological Psychiatry, 2014Co-Authors: Andre Der-avakian, James P. Kesby, Eric J. Nestler, Michelle S. Mazei-robison, Athina MarkouAbstract:Background: Anhedonia, or diminished interest or pleasure in rewarding activities, characterizes depression and reflects deficits in brain reward circuitries. Social stress induces Anhedonia and increases risk of depression, although the effect of social stress on brain reward function is incompletely understood. Methods: This study assessed the following: 1) brain reward function in rats (using the intracranial self-stimulation procedure) and protein levels of brain-derived neurotrophic factor and related signaling molecules in response to chronic social defeat, 2) brain reward function during social defeat and long-term treatment with the antidepressants fluoxetine (5 mg/kg/day) and desipramine (10 mg/kg/ day), and 3) forced swim test behavior after social defeat and fluoxetine treatment. Results: Social defeat profoundly and persistently decreased brain reward function, reflecting an enduring anhedonic response, in susceptible rats, whereas resilient rats showed no long-term brain reward deficits. In the ventral tegmental area, social defeat, regardless of susceptibility or resilience, decreased brain-derived neurotrophic factor and increased phosphorylated AKT, whereas only susceptibility was associated with increased phosphorylated mammalian target of rapamycin. Fluoxetine and desipramine reversed lower, but not higher, stress-induced brain reward deficits in susceptible rats. Fluoxetine decreased immobility in the forced swim test, as did social defeat. Conclusions: These results suggest that the differential persistent anhedonic response to psychosocial stress may be mediated by ventral tegmental area signaling molecules independent of brain-derived neurotrophic factor and indicate that greater stress-induced Anhedonia is associated with resistance to antidepressant treatment. Consideration of these behavioral and neurobiological factors associated with resistance to stress and antidepressant action may promote the discovery of novel targets to treat stress-related mood disorders.
-
Neural substrates of psychostimulant withdrawal-induced Anhedonia.
Current topics in behavioral neurosciences, 2009Co-Authors: Manoranjan S. D’souza, Athina MarkouAbstract:Psychostimulant drugs have powerful reinforcing and hedonic properties and are frequently abused. Cessation of psychostimulant administration results in a withdrawal syndrome characterized by Anhedonia (i.e., an inability to experience pleasure). In humans, psychostimulant withdrawal-induced Anhedonia can be debilitating and has been hypothesized to play an important role in relapse to drug use. Hence, understanding the neural substrates involved in psychostimulant withdrawal-induced Anhedonia is essential. In this review, we first summarize the theoretical perspectives of psychostimulant withdrawal-induced Anhedonia. Experimental procedures and measures used to assess Anhedonia in experimental animals are also discussed. The review then focuses on neural substrates hypothesized to play an important role in Anhedonia experienced after termination of psychostimulant administration, such as with cocaine, amphetamine-like drugs, and nicotine. Both neural substrates that have been extensively investigated and some that need further evaluation with respect to psychostimulant withdrawal-induced Anhedonia are reviewed. In the context of reviewing the various neurosubstrates of psychostimulant withdrawal, we also discuss pharmacological medications that have been used to treat psychostimulant withdrawal in humans. This literature review indicates that great progress has been made in understanding the neural substrates of Anhedonia associated with psychostimulant withdrawal. These advances in our understanding of the neurobiology of Anhedonia may also shed light on the neurobiology of nondrug-induced Anhedonia, such as that seen as a core symptom of depression and a negative symptom of schizophrenia.
-
Animal models and treatments for addiction and depression co-morbidity
Neurotoxicity Research, 2007Co-Authors: Neil E. Paterson, Athina MarkouAbstract:The high rates of co-morbidity of drug addiction with depression may be attributable to shared neurobiology. Here, we discuss shared neurobiological substrates in drug withdrawal and depression, with an emphasis on changes in brain reward circuitry that may underlie Anhedonia, a core symptom of depression and drug withdrawal. We explored experimentally whether clinical antidepressant medications or other treatments would reverse the Anhedonia observed in rats undergoing spontaneous nicotine or amphetamine withdrawal, defined operationally as elevated brain reward thresholds. The co-administration of selective serotonin reuptake inhibitors with a serotonin-1A receptor antagonist, or the tricyclic antidepressant desipramine, or the atypical antidepressant bupropion ameliorated nicotine or amphetamine withdrawal in rats. Thus, increases in monoaminergic neurotransmission, or neuroadaptations induced by increased monoaminergic neurotransmission, ameliorated depression-like aspects of drug withdrawal. Further, chronic pretreatment with the atypical antipsychotic clozapine, that has some efficacy in the treatment of the depression-like symptoms of schizophrenia, attenuated nicotine and amphetamine withdrawal. Finally, a metabotropic glutamate 2/3 receptor antagonist reversed threshold elevations associated with nicotine withdrawal. The effects of these pharmacological manipulations are consistent with the altered neurobiology observed in drug withdrawal and depression. Thus, these data support the hypothesis of common substrates mediating the depressive symptoms of drug withdrawal and those seen in psychiatric patients. Accordingly, the anhedonic state associated with drug withdrawal can be used to study the neurobiology of Anhedonia, and thus contribute to the identification of novel targets for the treatment of depression-like symptoms seen in various psychiatric and neurological disorders.
-
postcocaine Anhedonia an animal model of cocaine withdrawal
Neuropsychopharmacology, 1991Co-Authors: Athina Markou, George F KoobAbstract:: Cocaine use frequently occurs in episodic, prolonged binges. Following such a cocaine binge, the user suffers from severe depressive symptoms mixed with irritability and anxiety ("crash"). The present study was an attempt to develop an animal model of postcocaine depression or Anhedonia and to study the time course of this cocaine withdrawal symptom. Rats were allowed to self-administer cocaine intravenously for prolonged periods of time and their brain reward thresholds were then assessed using intracranial self-stimulation (ICSS) thresholds. ICSS thresholds were used operationally as a measure of the animals' "hedonic-anhedonic" state. It was found that during cocaine withdrawal ICSS thresholds were elevated compared to predrug baseline levels and to control animals' thresholds, reflecting an "anhedonic" state. The magnitude and duration of the "anhedonic" state was proportional to the amount of cocaine consumed during the binge. A measure of response latency provided evidence that this postcocaine elevation of thresholds is due to a desensitization of the reward pathways mediating ICSS reward and not to any nonspecific (e.g., performance) effects of the cocaine exposure.
Areej Eljawahri - One of the best experts on this subject based on the ideXlab platform.
-
does desire to pursue pleasurable activities matter the impact of pretransplantation Anhedonia on quality of life and fatigue in hematopoietic stem cell transplantation
Biology of Blood and Marrow Transplantation, 2020Co-Authors: Hermioni L Amonoo, Alyssa L Fenech, Joseph A Greer, Jennifer S Temel, Jeff C Huffman, Areej EljawahriAbstract:Anhedonia, the loss of the capacity to experience pleasure, is subjectively and biologically distinct from depressed mood. Few studies have specifically examined the association of pretransplantation Anhedonia with key functional outcomes (eg, health-related quality of life [QOL]) in patients with hematologic malignancies who have undergone hematopoietic stem cell transplantation (HSCT). Among 248 HSCT recipients enrolled in 2 intervention trials, we examined the associations between pretransplantation Anhedonia and both QOL and fatigue at 2 weeks and 6 months post-transplantation. Across time points, patients completed the Hospital Anxiety and Depression Scale, Functional Assessment of Cancer Therapy-Bone Marrow Transplant, and Functional Assessment of Cancer Therapy-Fatigue subscale, which we used to measure depressive symptoms, QOL and fatigue, respectively. Pretransplantation Anhedonia was assessed using the corresponding item in the Patient Health Questionnaire-9. The Functional Assessment of Cancer Therapy-Bone Marrow Transplant and the Functional Assessment of Cancer Therapy-Fatigue subscales were used to measure QOL and fatigue. Associations between pretransplantation Anhedonia and outcomes were assessed using regression analyses, adjusting for age, sex, transplant type, and intervention group. Ninety-eight patients (39.5%) reported pretransplantation Anhedonia, of whom 60 (61%) did not meet the criteria for elevated depressive symptoms. Pretransplantation Anhedonia was negatively associated with QOL at 2 weeks (B = -17.21; 95% confidence interval [CI], -23.05 to -11.30; P < .001) and at 6 months (B = -15.10; 95% CI, -21.51 to -8.69; P< .001). Pretransplantation Anhedonia was also negatively associated with fatigue (2 weeks: B = -9.35; 95% CI, -12.47 to -6.22; P< .001; 6 months: B = -5.68; 95% CI, -9.07 to -2.28; P= .001). The association between pretransplantation Anhedonia and QOL and fatigue remained significant after adjusting for depression scores. Pretransplantation Anhedonia is negatively and significantly associated with QOL and fatigue in HSCT recipients. These findings underscore the need to incorporate Anhedonia assessment in the evaluation and management of psychological distress in these patients.
-
does desire to pursue pleasurable activities matter the impact of pre transplant Anhedonia on quality of life and fatigue in hematopoietic stem cell transplantation
Biology of Blood and Marrow Transplantation, 2020Co-Authors: Hermioni L Amonoo, Alyssa L Fenech, Joseph A Greer, Jennifer S Temel, Jeff C Huffman, Areej EljawahriAbstract:BACKGROUND: Anhedonia, the loss of the capacity to experience pleasure, is subjectively and biologically distinct from depressed mood. Few studies have specifically examined the association of pre-transplant Anhedonia with key functional outcomes (e.g., health-related quality of life; QOL) in patients with hematologic malignancies who have received hematopoietic stem cell transplantation (HSCT). METHODS: Among 248 HSCT patients enrolled in two intervention trials, we examined the associations between pre-transplant Anhedonia and both QOL and fatigue at 2 weeks and 6 months post-transplant. Across time points, patients completed the Hospital Anxiety and Depression Scale, Functional Assessment of Cancer Therapy-Bone Marrow Transplant, and Functional Assessment of Cancer Therapy-Fatigue subscale, which we used to measure depressive symptoms, QOL and fatigue, respectively. Pre-transplant Anhedonia was assessed via the corresponding item in the Patient Health Questionnaire-9. The Functional Assessment of Cancer Therapy-Bone Marrow Transplant and the Functional Assessment of Cancer Therapy-Fatigue subscale were used to measure QOL and fatigue. Associations between pre-transplant Anhedonia and outcomes were assessed via regression analyses adjusting for age, gender, transplant type, and intervention group. RESULTS: 39.5% (n=98) of patients reported pre-transplant Anhedonia. Of the patients who reported pre-transplant Anhedonia, 61% (n=60) did not meet criteria for elevated depressive symptoms. Pre-transplant Anhedonia was negatively associated with QOL at 2 weeks (B=-17.21; 95% CI, -23.05 to -11.30; p<.001) and at 6 months (B=-15.10; 95% CI, -21.51 to -8.69; p<.001). Pre-transplant Anhedonia was also negatively associated with fatigue (2 weeks: B=-9.35; 95% CI, -12.47 to -6.22; p<.001; 6 months: B=-5.68; 95% CI, -9.07 to -2.28; p=.001). The association between pre-transplant Anhedonia and QOL and fatigue remained significant after adjusting for depression scores. CONCLUSIONS: Pre-transplant Anhedonia is negatively and significantly associated with QOL and fatigue in HSCT patients. These findings underscore the need to incorporate Anhedonia assessment in the evaluation and management of psychological distress in HSCT patients.
David H Zald - One of the best experts on this subject based on the ideXlab platform.
-
effort based decision making in major depressive disorder a translational model of motivational Anhedonia
Journal of Abnormal Psychology, 2012Co-Authors: Michael T Treadway, Nicholas A Bossaller, Richard C Shelton, David H ZaldAbstract:Anhedonia is a core feature of major depressive disorder (MDD), but the precise nature of anhedonic symptoms is unknown. Whereas Anhedonia has traditionally been viewed as a deficit in the experience of pleasure, more recent evidence suggests that reduced anticipation and motivation may also be a core feature of this symptom. Here, we provide data from a study in MDD patients and healthy controls using a translational measure of reward motivation, the Effort Expenditure for Rewards Task (EEfRT or “effort”). This task offers subjects a series of trials where they may choose to expend more or less effort for the opportunity to win varying amounts of monetary rewards. We found that MDD patients were less willing to expend effort for rewards than controls. Additionally, we observed that patients were less able to effectively use information about magnitude and probability of rewards to guide their choice behavior. Finally, within the MDD patient group, duration of the current episode was a significant negative predictor of EEfRT task performance. These findings offer novel support for theoretical models proposing that Anhedonia in MDD may reflect specific impairments in motivation and reward-based decision-making.
-
reconsidering Anhedonia in depression lessons from translational neuroscience
Neuroscience & Biobehavioral Reviews, 2011Co-Authors: Michael T Treadway, David H ZaldAbstract:Anhedonia is a core symptom of major depressive disorder (MDD), the neurobiological mechanisms of which remain poorly understood. Despite decades of speculation regarding the role of dopamine (DA) in anhedonic symptoms, empirical evidence has remained elusive, with frequent reports of contradictory findings. In the present review, we argue that this has resulted from an underspecified definition of Anhedonia, which has failed to dissociate between consummatory and motivational aspects of reward behavior. Given substantial preclinical evidence that DA is involved primarily in motivational aspects of reward, we suggest that a refined definition of Anhedonia that distinguishes between deficits in pleasure and motivation is essential for the purposes of identifying its neurobiological substrates. Moreover, bridging the gap between preclinical and clinical models of Anhedonia may require moving away from the conceptualization of Anhedonia as a steady-state, mood-like phenomena. Consequently, we introduce the term “decisional Anhedonia” to address the influence of Anhedonia on reward decision-making. These proposed modifications to the theoretical definition of Anhedonia have implications for research, assessment and treatment of MDD.
-
worth the eefrt the effort expenditure for rewards task as an objective measure of motivation and Anhedonia
PLOS ONE, 2009Co-Authors: Michael T Treadway, David H Zald, Joshua W Buckholtz, Ashley N Schwartzman, Warren LambertAbstract:Background Of the putative psychopathological endophenotypes in major depressive disorder (MDD), the anhedonic subtype is particularly well supported. Anhedonia is generally assumed to reflect aberrant motivation and reward responsivity. However, research has been limited by a lack of objective measures of reward motivation. We present the Effort-Expenditure for Rewards Task (EEfRT or “effort”), a novel behavioral paradigm as a means of exploring effort-based decision-making in humans. Using the EEfRT, we test the hypothesis that effort-based decision-making is related to trait Anhedonia. Methods/Results 61 undergraduate students participated in the experiment. Subjects completed self-report measures of mood and trait Anhedonia, and completed the EEfRT. Across multiple analyses, we found a significant inverse relationship between Anhedonia and willingness to expend effort for rewards. Conclusions These findings suggest that Anhedonia is specifically associated with decreased motivation for rewards, and provide initial validation for the EEfRT as a laboratory-based behavioral measure of reward motivation and effort-based decision-making in humans.
Gwenolé Loas - One of the best experts on this subject based on the ideXlab platform.
-
Anhedonia is associated with suicidal ideation independently of depression a meta analysis
Depression and Anxiety, 2018Co-Authors: Deborah Ducasse, Gwenolé Loas, Deborah Dassa, Carla Gramaglia, Patrizia Zeppegno, Sebastien Guillaume, Emilie Olie, Philippe CourtetAbstract:BACKGROUND: Anhedonia is considered a suicide risk factor in patients with major affective disorders. Here, we wanted to quantify the association between Anhedonia and current suicidal ideation according to the absence/presence of between-group differences for depressive scores and psychiatric disorders. METHODS: We performed a meta-analysis of data on studies retrieved from Medline, Web of Science, and PsycINFO from 1965 to 2016 using, among others, the terms (suicid* or depression) and Anhedonia. RESULTS: We identified 15 observational case-control studies that investigated the Anhedonia differences in individuals with and without current (i.e., within the past week, independently of the lifetime suicidality status) suicidal ideation (defined as thoughts of killing oneself). Overall, 657 subjects with and 6,690 subjects without current suicidal ideation could be compared. Anhedonia level was higher in the group with current suicidal ideation than in the group without, with a medium effect size (standardized mean difference = 0.57, z = 5.43, P < 0.001, 95% confidence interval, CI = 0.37-0.79). The association between Anhedonia and current suicidal ideation remained significant when controlling for depression and psychiatric disorders. The Anhedonia scales used in the selected studies did not allow investigating consummatory and motivational Anhedonia separately. CONCLUSION: Our major finding is the robust association between Anhedonia and current suicidal ideation, independently of depression. This is highly relevant for the clinicians' daily practice and might help improving suicidal risk detection and the development of new therapeutic strategies for suicide prevention.
-
relationships between Anhedonia suicidal ideation and suicide attempts in a large sample of physicians
PLOS ONE, 2018Co-Authors: Gwenolé Loas, Guillaume Lefebvre, Marianne Rotsaert, Yvon EnglertAbstract:Background The relationships between Anhedonia and suicidal ideation or suicide attempts were explored in a large sample of physicians using the interpersonal psychological theory of suicide. We tested two hypotheses: firstly, that there is a significant relationship between Anhedonia and suicidality and, secondly, that Anhedonia could mediate the relationships between suicidal ideation or suicide attempts and thwarted belongingness or perceived burdensomeness. Methods In a cross-sectional study, 557 physicians filled out several questionnaires measuring suicide risk, depression, using the abridged version of the Beck Depression Inventory (BDI-13), and demographic and job-related information. Ratings of Anhedonia, perceived burdensomeness and thwarted belongingness were then extracted from the BDI-13 and the other questionnaires. Results Significant relationships were found between Anhedonia and suicidal ideation or suicide attempts, even when significant variables or covariates were taken into account and, in particular, depressive symptoms. Mediation analyses showed significant partial or complete mediations, where Anhedonia mediated the relationships between suicidal ideation (lifetime or recent) and perceived burdensomeness or thwarted belongingness. For suicide attempts, complete mediation was found only between Anhedonia and thwarted belongingness. When the different components of Anhedonia were taken into account, dissatisfaction—not the loss of interest or work inhibition—had significant relationships with suicidal ideation, whereas work inhibition had significant relationships with suicide attempts. Conclusions Anhedonia and its component of dissatisfaction could be a risk factor for suicidal ideation and could mediate the relationship between suicidal ideation and perceived burdensomeness or thwarted belongingness in physicians. Dissatisfaction, in particular in the workplace, may be explored as a strong predictor of suicidal ideation in physicians.
-
Is State Anhedonia Characteristic of Parkinson’s Disease?
Advances in Aging Research, 2015Co-Authors: Gwenolé Loas, Pierre KrystkowiakAbstract:Anhedonia, the lowered ability to experience pleasure, is one of the non-motor symptoms in Parkinson’s disease. Recently, the distinction between consummatory and anticipatory Anhedonia has been proposed and Anhedonia, notably in PD, could constitute a stable characteristic (Anhedonia-trait) or secondary symptom (Anhedonia-state). Several studies, using healthy control groups, reported high state consummatory and anticipatory Anhedonia in PD using the Snaith Hamilton Pleasure Scale (SHAPS), but when control groups included subjects with different illnesses no significant differences were reported. The aim of the present study was to compare PD subjects with subjects presenting a non-Parkinson motor neurological disease on the Anhedonia subscale of the Beck Depression Inventory (BDI-II). This subscale rated consummatory and anticipatory Anhedonia state. No significant difference was reported. This result confirmed that PD subjects were not characterized by high levels of state Anhedonia when the subjects were compared to subjects with a different disease. Contrary to trait consummatory Anhedonia, state Anhedonia could be nonspecific to Parkinson’s disease.
-
Relationship between anticipatory, consummatory Anhedonia and disorganization in schizotypy
BMC Psychiatry, 2014Co-Authors: Gwenolé Loas, Annie Verrier, Jean-louis MonestèsAbstract:The disorganized and negative dimensions of schizotypy are characterized by cognitive disorganization and Anhedonia, respectively. The aim of the study was to investigate the relationships between these two dimensions of schizotypy by taking into account ambivalence and the distinction between consummatory and anticipatory Anhedonia. Dimensional analysis and categorical analysis were performed on two different samples (N = 400 and 399) of university students. Self-reported scales were used to measure cognitive disorganization, anticipatory and consummatory Anhedonia, and ambivalence. Dimensional analysis using confirmatory factorial analysis examined various models of disorganized and negative schizotypy and categorical analysis compared the scores on anticipatory, consummatory Anhedonia and ambivalence scales between various groups of subjects presenting either disorganized schizotypy or negative schizotypy or free of schizotypy. The disorganized dimension of schizotypy was characterized by schizotypal ambivalence and anticipatory Anhedonia, while the negative dimension of schizotypy was characterized by anticipatory and consummatory Anhedonia. The results suggested firstly that ambivalence was not specific of disorganized schizotypy and secondly that anticipatory Anhedonia was not specific of negative schizotypy.
-
Anhedonia and negative symptomatology in chronic schizophrenia
Comprehensive Psychiatry, 2004Co-Authors: Gwenolé Loas, P. Boyer, A. LegrandAbstract:Abstract The relationships between negative symptomatology and Anhedonia have been studied on 61 subjects who had Research Diagnostic Criteria for chronic schizophrenia. Negative symptomatology was rated by the negative subscales of the Kay Positive and Negative Syndrome Scale (PANSS) and of the Brief Psychiatric Rating Scale (BPRS). Anhedonia was rated by the Physical Anhedonia Scale of Chapman (PAS), the Fawcett-Clark Pleasure Capacity Scale-Physical Pleasure (FCPCS-PP), and the social interest subscale (SIS) of the Nurse Observation Scale for Inpatients (NOSIE30). Pearson correlations were calculated between negative and Anhedonia scales. Schizophrenics were dichotomized first into negatives and positives using the composite score of the PANSS, and second into low and high negatives using the negative subscale of the PANSS. For each dichotomy, the corresponding subgroups were compared on Anhedonia scales using Student's t test. The results have shown no significant correlations between negative and Anhedonia scales (PAS and FCPCS-PP). There were no significant differences concerning the PAS and the FCPCS-PP between negative and positive subgroups of schizophrenics and between low- and high-negative subgroups. Anhedonia is not a negative symptom. Our results confirm the reported studies on subjective experiences in schizophrenia. A search for more restricted forms of schizophrenia characterized by severe Anhedonia is needed.